| Name | Title | Contact Details |
|---|
Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its proprietary gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.
Bristol-Myers Squibb Canada is a Saint-Laurent, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
A global leader in blood management, blood safety, therapeutic apheresis, cell therapy and cell collections. Terumo BCT believes in the potential of blood to do even more for patients than it does today.
HealthCore is a Wilmington, DE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
The RADIANCE-HTN Clinical study is a randomized, controlled study to evaluate the Paradise Renal Denervation System intended to treat high blood pressure. The study will be in up to 40 hospitals in 5 countries (US, France, Germany, The Netherlands, UK...